Need help choosing the right code?
Ask CasePilot about procedures, modifiers, bundling, and coding guidance.
Try CasePilot© Copyright 2026 American Medical Association. All rights reserved.
The CPT® Code 87539 refers to the detection of the infectious agent HIV-2 through nucleic acid techniques, specifically focusing on quantification. This procedure involves the measurement of HIV-2 viral load in a patient's sample, which is crucial for monitoring the progression of the infection and the effectiveness of treatment. The process includes reverse transcription, which is a method used to convert RNA into DNA, allowing for the amplification and subsequent quantification of the viral genetic material. HIV-2 is one of the two main serotypes of the human immunodeficiency virus, the other being HIV-1. Both types can lead to acquired immunodeficiency syndrome (AIDS), a condition characterized by a severely weakened immune system. The transmission of HIV-2 can occur through various means, including sexual contact, unscreened blood transfusions, sharing of needles, and from mother to child during childbirth or breastfeeding. The detection of HIV-2 is essential for timely intervention and management of the infection, as it helps healthcare providers assess the viral load and adjust treatment plans accordingly. The procedure typically requires a blood sample, from which the nucleic acids are extracted and analyzed to determine the presence and quantity of HIV-2, thereby providing critical information for patient care.
© Copyright 2026 Coding Ahead. All rights reserved.
The procedure associated with CPT® Code 87539 is indicated for the following conditions:
The procedure for CPT® Code 87539 involves several detailed steps to ensure accurate detection and quantification of HIV-2. First, a blood sample is collected from the patient. This sample is then processed to isolate the leukocytes, which are the white blood cells that may contain the viral nucleic acids. The red blood cells in the sample are selectively lysed, allowing the leukocytes to remain intact. Following this, the leukocytes are pelleted and washed multiple times to purify the sample further. Once the leukocytes are prepared, DNA is extracted from the pellet. This step is crucial as it allows for the amplification of proviral HIV-2 DNA. The amplification process typically employs reverse transcription polymerase chain reaction (RT-PCR), which creates multiple copies of the HIV-2 nucleic acids, especially important when the viral load is low. After amplification, the detection component is utilized to ascertain the presence of HIV-2 DNA in the specimen. Finally, the quantification step evaluates the amount of the infectious agent in the sample, providing a measurement of the HIV-2 viral load, which is essential for assessing the patient's response to treatment.
After the procedure associated with CPT® Code 87539, the patient may not require any specific post-procedure care, as the blood sample collection is minimally invasive. However, it is important for healthcare providers to communicate the results of the test to the patient promptly. The results will inform the ongoing management of the patient's HIV-2 infection, including any necessary adjustments to treatment plans based on the quantified viral load. Patients may be advised to follow up with their healthcare provider to discuss the implications of the test results and any further steps in their treatment regimen. Regular monitoring may be recommended to track changes in viral load over time, ensuring effective management of the infection.
| Short Descr | HIV-2 QUANT&REVRSE TRNSCRIPJ | Medium Descr | IADNA HIV-2 QUANT & REVERSE TRANSCRIPTION | Long Descr | Infectious agent detection by nucleic acid (DNA or RNA); HIV-2, quantification, includes reverse transcription when performed | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | CLIA Waived (QW) | No | APC Status Indicator | Conditionally packaged laboratory tests | Type of Service (TOS) | 5 - Diagnostic Laboratory | Berenson-Eggers TOS (BETOS) | T1H - Lab tests - other (non-Medicare fee schedule) | MUE | 1 | CCS Clinical Classification | 206 - Microscopic examination (bacterial smear, culture, toxicology) |
| 90 | Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number. | GA | Waiver of liability statement issued as required by payer policy, individual case |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2014-01-01 | Changed | Description Changed |
| 2013-01-01 | Changed | Description Changed |
| 2011-01-01 | Changed | Short description changed. |
| 1998-01-01 | Added | First appearance in code book in 1998. |
Get instant expert-level medical coding assistance.